spacer
home > epc > Winter 2016
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2016

   
Text
PDF
bullet
Business and Finance
Drug Prices

Adding Value


Putting a price tag on drugs is a challenge – but by implementing two increasingly common pricing strategies, it is possible to satisfy both seller and buyer, claim ERT’s Stephen Raymond and Matthew Reaney.
 
view
download pdf
bullet
Marketplace & Business
Mergers and Acquisitions

Shared Vision


Dealing with employees is, arguably, the most important aspect of M&A. Mike Straw at Achieve Breakthrough reveals what company executives can do to ensure a smooth transition.
 
view
download pdf
M&A Activity Report

Across the Border


There is a noticeable shift towards acquiring in growing markets overseas, and investment in personalised medicine – EPC summaries these twin trends within M&A activity.
 
view
download pdf
bullet
Legal & Regulatory
Clinical Evaluation

Conform to the Norm: Part 1


In this first of a two-part article, Terry Winchell at GCP Innovative Dynamics offers an in-depth analysis of the FDA clinical investigator disqualification process, including early beginnings and how the FDA interprets its role.
 
view
download pdf
bullet
Electronic Solutions
Pharmacovigilance and Social Media

Keep Talking


Digital media is set to alter the way patients and companies communicate, observes Supriya Desai at Sciformix Corporation, but this change is not without risk.
 
view
download pdf
bullet
Review
Event Review

Latest on Life Sciences


EPC reports on the CMS Global Lifesciences Forum 2015, in which the biggest issues driving the sector were discussed.
 
view
download pdf
bullet
Manufacturing Environment
Medical Device Regulations

Step by Step

Chris Rule
at Maetrics advises medical device manufacturers to take great care in producing clinical evaluation reports, and proposes a 10-step plan to successfully comply with new regulations in 2018.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement